V I S I T
WORLD’S CLINICAL LABORATORY NEWS LEADER ISSN 1068-1760
Vol.41 No.1 • 2-3/2024
DAILY CLINICAL LAB NEWS
®
I
N
T
E
POC Test for Risk of Severe Dengue
R
N
A
T
I
O
Novel Screening Test Capable of Identifying 18 Early-Stage Cancers
engue is typically a mild illness, yet approximately 15% of cases can progress to critical dengue, demanding intensive care and monitoring. Current early detection methods for severe dengue, such as PCR and ELISA tests conducted on blood
D
ancer, responsible for onesixth of all global deaths, presents a formidable challenge, particularly because early detection is crucial for improving survival rates. However, current screening tests often fall short due to factors like invasiveness, cost,
C
and limited accuracy in detecting early-stage diseases. In response to this challenge, researchers have now developed an innovative blood test that can identify 18 types of early-stage cancers across various major organs in the human body.
Cont’d on page 6
Cont’d on page 13
AI Accurately Predicts Cancer Outcomes from Tissue Samples
N
A
L
Test Screens for Genetic Diseases in Fetuses urrently, the first-generation Non-Invasive Prenatal Test (NIPT) is used widely to screen fetuses for common chromosomal disorders, mainly focusing on conditions like Down syndrome and other anomalies resulting from significant chromosomal changes. However, many congenital disorders stem from more subtle alterations in fetal DNA. To detect these, a compre-
C
Cont’d on page 4
Measuring Chemotherapy Results in Bone Cancer he calculation of Percent Necrosis (PN) — the proportion of a tumor considered inactive or “dead” following chemotherapy — serves as a vital predictor of survival outcomes in osteosarcoma, a type of bone cancer. For instance, a PN of 99% signifies that 99% that the tumor is dead, indicating the patient’s positive response to chemotherapy and potentially better survival
T
n innovative AI model is now capable of examining the spatial organization of cells within tissue samples, offering precise predictions on cancer patient outcomes as well as indications for prognosis and tailored treatment.
A
See article on page 5
Cont’d on page 10 V
I
S
I
T
LINKXPRESS COM R E A D E R
S E R V I C E
®
P O R T A L
Renew/Start your Free Subscription Access Interactive Digital Magazine Instant Online Product Information:
First Affordable and Rapid Test for Beta Thalassemia emoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world’s population, with 40,000 newborns diagnosed annually. Beta thalassemia patients often require
H
®
If your subscription is not renewed every 12 months your Free Subscription may be automatically discontinued
Clinical News . . . . 3-16 IFCC News . . . . 17-20 Industry News .. . . . 21
Handheld Device Detects Fentanyl in Urine in Seconds
®
Mark code(s) of interest on 3 LinkXpress inquiry matrix
LabMedica EXPO . 6-16
Cont’d on page 8
Identify LinkXpress codes of 1 interest as you read magazine on LinkXpress.com 2 toClick reach reader service portal
INSIDE
entanyl, a synthetic opioid recognized by the Centers for Disease Control and Prevention as being 50 times more potent than heroin and 100 times more potent than morphine, is often illicitly combined with other drugs. Just 2 milligrams of fentanyl,
F
roughly equivalent to 10 to 15 grains of table salt, can be fatal. Research has shown that fentanyl can be detected in urine up to 72 hours after use. Now, researchers have developed a first-of-its-kind, handheld device that is capable of accurately detecting fentanyl Cont’d on page 14
Events Calendar . . 22 PUBLISHED IN COOPERATION WITH
International Federation of Clinical Chemistry and Laboratory Medicine
GLOBETECH >>> MEDIA <<<